Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland

References

• Mental health: schizophrenia. http://www.who.int/mental_health/management/schizophrenia/en/. Accessed October 10, 2011
   Google Scholar
• The global burden of disease: 2004 update. Geneva: World Health Organisation, 2008
   Google Scholar
• Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schiz Bull 2004;30:279-93
   PubMed Web of Science ®Google Scholar
• Karagianis J, Novick D, Pecanek J, et al. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract 2009;63:1578-88
   PubMed Web of Science ®Google Scholar
• Perälä J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar disorders in a general population. Arch Gen Psychiatry 2007;64:19-28
   PubMed Web of Science ®Google Scholar
• Juvonen H, Reunanen A, Haukka J, et al. Incidence of schizophrenia in a nationwide cohort of patients with type 1 diabetes mellitus. Arch Gen Psychiatry 2007;64:894-9
   PubMedGoogle Scholar
• Arajärvi R, Suvisaari J, Suokas J, et al. Prevalence and diagnosis of schizophrenia based on register, case record and interview data in an isolated Finnish birth cohort born 1940–1969. Soc Psychiatry Psychiatr Epidemiol 2005;40:808-16
   PubMed Web of Science ®Google Scholar
• Teperi J, Porter ME, Vuorenkoski L, et al The Finnish health care system: a value-based perspective. Sitra Reports 82. Helsinki: Edita Prima Ltd, 2009
   Google Scholar
• OECD report criticises Finland for inefficient treatment of mental illness. Helsingin Sanomat. http://www.hs.fi/english/article/OECD+report+criticises+Finland+for+inefficient+treatment+of+mental+illness/1135251638800. Accessed October 10, 2011
   Google Scholar
• Nasrallah H. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007;115:260-7
   PubMed Web of Science ®Google Scholar
• Adams CE, Fenton MKP, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-9
   PubMed Web of Science ®Google Scholar
• Möller HJ. Novel antipsychotics and negative symptoms. Int Clin Psychopharmacol 1998;13(3 Suppl):S43-7
   Google Scholar
• Kane J, Eerdekens M, Lindenmayer J-P, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-32
   PubMed Web of Science ®Google Scholar
• Mehnert A, Diels J. Impact of administration interval on treatment retention with long-acting antipsychotics in schizophrenia. Presented at the Tenth Workshop on Costs and Assessment in Psychiatry -Mental Health Policy and Economics, Venice, Italy, March 25-27, 2011
   Google Scholar
• European Medicines Agency. Assessment report for Zypadhera. Doc. Ref EMEA/608654/2008. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000890/WC500054428.pd. Procedure No. EMEA/H/C/000890, 1-63. 2008. Accessed August 8, 2011.
   Google Scholar
• European Medicines Agency. Zypadhera® product monograph. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000890/WC500054429.pdf. 20-4-2010. Accessed August 8, 2011.
   Google Scholar
• European Medicines Agency. Xeplion® opinion. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002105/smops/Positive/human_smop_000162.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d127. Accessed October 10, 2011.
   Google Scholar
• European Medicines Agency. Xeplion® product monograph. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002105/WC500103317.pdf. Accessed October 10, 2011
   Google Scholar
• Detke H, Mcdonnell D, Brunner E, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry 2010;10:32
   PubMed Web of Science ®Google Scholar
• Devadason P. Practical limitations of prescribing olanzapine depot (Relprevv). Australas Psychiatry 2010;18:269.
   PubMed Web of Science ®Google Scholar
• Alphs L, Gopal S, Karcher K, et al. Are long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium sedation syndrome? An assessment of safety databases. Curr Drug Saf 2011;6:43-5
   PubMedGoogle Scholar
• Einarson TR, Vicente C, Zilbershtein R, et al. Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway. Acta Neuropsychiatrica 2012 (In press). Article first published online: 11 JUL 2012 | DOI: 10.1111/j.1601-5215.2012.00670.x
   Google Scholar
• European Medicines Agency. Risperdal Consta® product monograph. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Risperdal_Consta_30/WC500008170.pdf. Accessed October 10, 2011
   Google Scholar
• Gopal S, Vijapurkar U, Lim P, et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol 2010;25:685-97
   PubMed Web of Science ®Google Scholar
• Fleischhacker W, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol 2011;22:1-12
   Google Scholar
• Gopal S, Hough D, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010;25:247-56
   PubMed Web of Science ®Google Scholar
• Pandina GJ, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:218-26
   PubMed Web of Science ®Google Scholar
• Hough D, Lindenmayer J-P, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1022-31
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010;35:2072-82
   PubMed Web of Science ®Google Scholar
• Pandina GJ, Lindenmayer J-P, Lull JM, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010;30:235-44
   PubMed Web of Science ®Google Scholar
• Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schiz Res 2010;116:107-17
   PubMed Web of Science ®Google Scholar
• Kissling W, Heres S, Lloyd K, et al. Direct transition to long-acting risperidone - analysis of long-term efficacy. J Psychopharmacol 2005;19:15-21
   PubMed Web of Science ®Google Scholar
• Lee M-S, Ko Y-H, Lee S-H, et al. Long-term treatment with long-acting risperidone in Korean patients with schizophrenia. Hum Psychopharmacol 2006;21:399-407
   PubMed Web of Science ®Google Scholar
• Lindenmayer J-P, Khan A, Eerdekens M, et al. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 2007;17:138-44
   PubMed Web of Science ®Google Scholar
• Olivares J, Rodrigues-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-96
   PubMed Web of Science ®Google Scholar
• Kane J, Detke H, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010;167:181-9
   PubMed Web of Science ®Google Scholar
• Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008;69:790-9
   PubMed Web of Science ®Google Scholar
• Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005;15:111-17
   PubMed Web of Science ®Google Scholar
• Eerdekens M, Van Hove I, Remmerie B, et al. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 2004;70:91-100
   PubMed Web of Science ®Google Scholar
• Olivares J, Peuskens J, Pecanek J, et al. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 2009;25:2197-206
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Faries D, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67:453-60
   PubMed Web of Science ®Google Scholar
• Weiden P, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-91
   PubMed Web of Science ®Google Scholar
• Morken G, Widen J, Gråwe R. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008;8:32.
   PubMed Web of Science ®Google Scholar
• Simonsen E, Friis S, Opjordsmoen S, et al. Early identification of non-remission in first-episode psychosis in a two-year outcome study. Acta Psychiatr Scand 2010;122:375-83
   PubMed Web of Science ®Google Scholar
• Wahlbeck K, Cheine M, Essali A, et al. Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999;156:990-9
   PubMed Web of Science ®Google Scholar
• Ministry of Social Affairs and Health, Finland. Guidelines for preparing a health economic evaluation. Helsinki, 2009. http://www.ispor.org/PEguidelines/source/GuidelinesinFinland_EnglishVersion.pdf. Accessed October 10, 2011
   Google Scholar
• Finland inflation rate (Consumer prices). http://www.indexmundi.com/finland/inflation_rate_(consumer_prices).html. Accessed October 10, 2011
   Google Scholar
• SLD price. Suomen LääkeData Oy (Finland). Helsinki: IMS Health Oy. http://www.sld.fi/finland.html. Accessed October 10, 2011
   Google Scholar
• Hujanen T, Kapienen S, Tuominen U, et al. Terveydenhuollon yksikkökustannukset Suomessa vuonna 2006. Helsinki: Stakes, 2008. http://www.stakes.fi/verkkojulkaisut/tyopaperit/T3-2008-VERKKO.pdf. Accessed December 1, 2011
   Google Scholar
• Hus Palveluhinnasto 2011. Osa 1, Tuotteistetut sairaanhoidolliset palvelut; Osa 2 Suoriteperusteiset sairaanhoidolliset palvelut. Helsinki: Helsingin Ja Uudenmaan Sairaanhoitopiiri (Hospital District of Helskinki and UUsimaa), http://www.hus.fi/default.asp?path=1,28,820,823,3018. Accessed December 1, 2011
   Google Scholar
• Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008;6:105.
   PubMed Web of Science ®Google Scholar
• Cummins C, Stevens A, Kisely S. The use of olanzapine as a first and second choice treatment in schizophrenia. A West Midlands Development and Evaluation Committee Report. Birmingham, UK: Department of Public Health & Epidemiology, University of Birmingham, 1998
   Google Scholar
• Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schiz Res 2004;71:155-75
   PubMed Web of Science ®Google Scholar
• Oh PI, Lanctôt KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ 2001;4:137-56
   Google Scholar
• Revicki DA, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Int Clin Psychopharmacol 1996;11:101-8
   PubMed Web of Science ®Google Scholar
• ATC/DDD index 2012. Oslo: WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atc_ddd_index/. Accessed December 2, 2012
   Google Scholar
• The World Fact Book: Finland. https://www.cia.gov/library/publications/the-world-factbook/geos/fi.html. Accessed December 2, 2011
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE). http://www.nice.org.uk/. Accessed December 5, 2011
   Google Scholar
• Yahoo Finance Currency Converter. http://ca.finance.yahoo.com/currencies/converter/#from=GBP;to=EUR;amt=1. Accessed December 4, 2011
   Google Scholar
• Koskinen H, Martikainen JE, Maljanen T. Antipsychotics and antidepressants: an analysis of cost growth in Finland from 1999 to 2005. Clin Ther 2009;31:1469-77
   PubMedGoogle Scholar
• Niskanen P, Pihkanen TA. A comparative study of home treatment and hospital care in the treatment of schizophrenic and paranoid psychotic patients. Acta Psychiatr Scand 1971;47:271-7
   Google Scholar
• Einarson TR, Zilbershtein R, Vicente V, et al. Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece. Ann Gen Psychiatry 2012;11:18
   PubMed Web of Science ®Google Scholar
• All Wales Medicines Strategy Group. Final appraisal report: Olanzapine depot (ZypAdhera®), Lilly UK. Advice No: 1510. Penarth, Wales: All Wales Medicines Strategy Group. 2010. http://www.wales.nhs.uk/sites3/Documents/371/olanzapine%20depot%20(ZypAdhera)%20schizophrenia.pdf. Accessed October 10, 2011
   Google Scholar
• Farahati F, Boucher M, Moulton K, et al. Atypical antipsychotic monotherapy for schizophrenia: clinical review and economic evaluation of first year of treatment [Technology report number 91]. Ottawa: Canadian Agency for Drugs and Technologies in Heath, 2007
   Google Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin 2011;27:713-30
   PubMed Web of Science ®Google Scholar
• Suokas JT, Perala J, Suominen K, et al. Epidemiology of suicide attempts among persons with psychotic disorder in the general population. Schiz Res 2010;124:22-8
   PubMed Web of Science ®Google Scholar
• Alaraisanen A, Miettunen J, Rasanen P, et al. Suicide rate in schizophrenia in the Northern Finland 1966 Birth Cohort. Soc Psychiatr Psychiatr Epidemiol 2009;44:1107-10
   PubMed Web of Science ®Google Scholar
• Honkonen T, Henriksson M, Koivisto AM, et al. Violent victimization in schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2004;39:606-12
   PubMed Web of Science ®Google Scholar
• Laajasalo T, Hakkanen H. Excessive violence and psychotic symptomatology among homicide offenders with schizophrenia. Crim Behav Ment Health 2006;16:242-53
   PubMedGoogle Scholar